Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Serum osmolality

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Serum osmolality. Displaying page 1 of 1.
    EudraCT Number: 2008-003774-17 Sponsor Protocol Number: 483-001 Start Date*: 2008-08-01
    Sponsor Name:Vantia Ltd
    Full Title: A double-blind, placebo-controlled dose response study to investigate pharmacodynamics and pharmacokinetics of single and repeated oral doses of VA106483 in elderly male subjects
    Medical condition: Nocturia.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029446 Nocturia LLT
    Population Age: Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005319-66 Sponsor Protocol Number: 2005/W/AN/02 Start Date*: 2006-06-02
    Sponsor Name:Research and Development Office, Royal Infirmary of Edinburgh
    Full Title: A comparative study of HyperHAES (7.2% NACL and 6% hydroxyethyl starch) and 20% mannitol in the treatment of elevated intracranial pressure after brain injry
    Medical condition: elevated intracranial pressure after brain injury
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014774-18 Sponsor Protocol Number: 09063 Start Date*: 2009-10-29
    Sponsor Name:University of Nottingham
    Full Title: The effects of balanced and unbalanced crystalloids and colloids on serum biochemistry and visceral blood flow: A two-phase, double-blind, randomised cross-over study
    Medical condition: This is a healthy volunteer study investigating the effect of balanced and unbalanced fluid infusions on serum electrolytes, osmolality and acid/base balance. In addition we are examining the role ...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004943-35 Sponsor Protocol Number: 5122016 Start Date*: 2017-03-01
    Sponsor Name:Radboud University Medical Center
    Full Title: Stimulation of ADH independent urine concentration in healthy volunteers
    Medical condition: healthy volunteers; the information of this pilot study will be used in the care of patients with diabetes insipidus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007941-10 Sponsor Protocol Number: EFC10102 Start Date*: 2008-06-11
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of two doses of Satavaptan (SR121463B) Versus Placebo in Patients with Dilutional Hyponatremia du...
    Medical condition: Dilutional hyponatraemia. MedRA term "HYPONATRAEMIA"
    Disease: Version SOC Term Classification Code Term Level
    10.1 10021036 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) HU (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002531-27 Sponsor Protocol Number: FE106483 CS005 Start Date*: 2005-11-09
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: The PEACE Study: Investigating the Pharmacodynamics and Pharmacokinetics of FE 106483 Tablets in a Single Dose Study in Children with Nocturnal Enuresis. A Randomised, Double-Blind and Placebo-Cont...
    Medical condition: Nocturnal Enuresis.
    Disease: Version SOC Term Classification Code Term Level
    7.1 10002774 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005047-21 Sponsor Protocol Number: SIRENA II Start Date*: 2007-12-24
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: Effects of Sirolimus on disease progression in patients with Autosomal Dominant Polycystic Kidney Disease and severe renal insufficiency
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010428 Congenital cystic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001846-24 Sponsor Protocol Number: 1 Start Date*: 2016-06-29
    Sponsor Name:Antwerp University Hospital
    Full Title: Metabolism of Isotonic versus Hypotonic Maintenance Solutions in fasting healthy Adults (MIHMoSA), a Single-Blind Randomized Crossover Trial
    Medical condition: Healthy adult volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004152-10 Sponsor Protocol Number: EMPATHY Start Date*: 2020-01-30
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Evaluating the Short-Term Renal and Systemic Effects of SGLT2 Inhibition in Non-Diabetic Patients at Risk of Accelerated GFR Decline Because of Glomerular Hyperfiltration: a sequential OFF-ON-OFF S...
    Medical condition: Obesity Renal chronic disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    21.1 100000004857 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002268-28 Sponsor Protocol Number: ULA04 Start Date*: 2020-03-10
    Sponsor Name:Department of Hepatology and Gastroenterology, Aarhus University Hospital
    Full Title: Single-center, randomized, double-blind, placebo-controlled clinical trial for the safety, tolerability and efficacy of ularitide in cirrhosis patients with refractory ascites.
    Medical condition: Liver cirrhosis with refractory ascites.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    20.0 10017947 - Gastrointestinal disorders 10003445 Ascites PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-005239-25 Sponsor Protocol Number: CPR-SFY5904-EN-E01 Start Date*: 2005-07-06
    Sponsor Name:Sanofi-Synthelabo Research
    Full Title: An open-label, multicenter study evaluating the long-term safety and efficacy of SR121463B in patients with Syndrome of Inappropriate Antidiuretic Hormone Secretion.
    Medical condition: Syndrome of Inappropriate Antidiuretic Hormone (SIADH) with serum sodium between 115 and 132 mmol/L.
    Disease: Version SOC Term Classification Code Term Level
    7.1 10040626 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005552-41 Sponsor Protocol Number: ALADIN Start Date*: 2006-02-20
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: Effect of long-acting somatostatin on disease progression in nephropathy due to autosomal dominant polycystic disease a long-term three year follow-up study
    Medical condition: Autosomal Dominant Polycystic Kidney Disease ADPKD
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038359 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004628-40 Sponsor Protocol Number: MRX-801 Start Date*: 2021-01-29
    Sponsor Name:Mirum Pharmaceuticals Inc
    Full Title: Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis ...
    Medical condition: Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10076033 Progressive familial intrahepatic cholestasis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10053870 Alagille syndrome PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019025-33 Sponsor Protocol Number: 156-09-284 Start Date*: 2010-08-31
    Sponsor Name:Otsuka Pharmaceutical Development Commercialization, Inc.
    Full Title: A Phase IIa, Single-Center Study, Investigating the Short-Term Renal Hemodynamic Effects, Safety and Pharmacokinetics/Pharmacodynamics of Oral Tolvaptan (OPC-41061) in Subjects with Autosomal Domin...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002721-99 Sponsor Protocol Number: CT114-2022-01 Start Date*: 2023-03-28
    Sponsor Name:Klinikum Nürnberg
    Full Title: Natriuretic-ureothelic adaptation of body fluid homeostasis during SGLT-2 inhibition and/or mineralocorticoid receptor modulation in patients with chronic kidney disease. A 4-arm, double-blind, dou...
    Medical condition: Stage 3 chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-006609-25 Sponsor Protocol Number: MOOD-HF Start Date*: 2008-05-27
    Sponsor Name:Julius Maximilians Universität Würzburg
    Full Title: Effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in Depressed Heart Failure patients
    Medical condition: To investigate the effects of selective serotonin re-uptake inhibition with the SSRI escitalopram on morbidity and mortality in depressed patients with CHF. The primary endpoint is the time to a fi...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000187-42 Sponsor Protocol Number: 156-12-298 Start Date*: 2016-10-24
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind, Placebo-controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy of Tolvaptan followed by a Two Year Open-l...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003786-20 Sponsor Protocol Number: S320.2.011 Start Date*: Information not available in EudraCT
    Sponsor Name:Solvay Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Randomized, Multi-Center, Dose-Finding Study of SLV320, a Selective A1 Adenosine Receptor Antagonist, to Evaluate the Effect on Renal Function and Safety in Subj...
    Medical condition: Acute Decompensated Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002067-18 Sponsor Protocol Number: B12CS-B13CS Start Date*: 2018-12-11
    Sponsor Name:Advicenne
    Full Title: A multicentre, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses...
    Medical condition: Cystinuria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011778 Cystinuria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000674-73 Sponsor Protocol Number: LJP 394-90-14 Start Date*: 2006-08-11
    Sponsor Name:La Jolla Pharmaceutical Company
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM, PARALLEL-GROUP, MULTICENTER, MULTINATIONAL SAFETY AND EFFICACY TRIAL OF 300 MG AND 900 MG OF ABETIMUS SODIUM IN SYSTEMIC LUPUS ERYTHEMATOS...
    Medical condition: Systemic lupus erythematosus patients with a history of renal disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042945 Systemic lupus erythematosus LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) PT (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 08:34:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA